218 related articles for article (PubMed ID: 36809706)
1. Advances in the development of phosphodiesterase-4 inhibitors.
Li G; He D; Cai X; Guan W; Zhang Y; Wu JQ; Yao H
Eur J Med Chem; 2023 Mar; 250():115195. PubMed ID: 36809706
[TBL] [Abstract][Full Text] [Related]
2. Advances in the Development of Phosphodiesterase-4 Inhibitors.
Peng T; Qi B; He J; Ke H; Shi J
J Med Chem; 2020 Oct; 63(19):10594-10617. PubMed ID: 32255344
[TBL] [Abstract][Full Text] [Related]
3. PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes.
Jin J; Mazzacuva F; Crocetti L; Giovannoni MP; Cilibrizzi A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511275
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions.
Parikh N; Chakraborti AK
Curr Med Chem; 2016; 23(2):129-41. PubMed ID: 26572614
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
7. Advances in the development of phosphodiesterase 7 inhibitors.
Huang JX; Zhu BL; Xu JP; Zhou ZZ
Eur J Med Chem; 2023 Mar; 250():115194. PubMed ID: 36796299
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 4 inhibitors in diabetic nephropathy.
Ookawara M; Nio Y
Cell Signal; 2022 Feb; 90():110185. PubMed ID: 34785349
[TBL] [Abstract][Full Text] [Related]
10. TAS-203, an oral phosphodiesterase 4 inhibitor, exerts anti-inflammatory activities in a rat airway inflammation model.
Demizu S; Asaka N; Kawahara H; Sasaki E
Eur J Pharmacol; 2019 Apr; 849():22-29. PubMed ID: 30716315
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Lipworth BJ
Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
[TBL] [Abstract][Full Text] [Related]
12. Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement.
Wei X; Yu G; Shen H; Luo Y; Shang T; Shen R; Xi M; Sun H
Bioorg Chem; 2023 Jan; 130():106278. PubMed ID: 36413930
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
Al-Sajee D; Yin X; Gauvreau GM
Expert Opin Pharmacother; 2019 Apr; 20(5):609-620. PubMed ID: 30722707
[TBL] [Abstract][Full Text] [Related]
14. PDE4 inhibitors for disease therapy: advances and future perspective.
Du B; Luo M; Ren C; Zhang J
Future Med Chem; 2023 Jul; 15(13):1185-1207. PubMed ID: 37470147
[TBL] [Abstract][Full Text] [Related]
15. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.
Abbott-Banner KH; Page CP
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):365-76. PubMed ID: 24517491
[TBL] [Abstract][Full Text] [Related]
16. Selective PDE inhibitors as novel treatments for respiratory diseases.
Page CP; Spina D
Curr Opin Pharmacol; 2012 Jun; 12(3):275-86. PubMed ID: 22497841
[TBL] [Abstract][Full Text] [Related]
17. Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS.
Bodkhe S; Nikam M; Sherje AP; Khan T; Suvarna V; Patel K
Int Immunopharmacol; 2020 Nov; 88():106906. PubMed ID: 33182057
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of a novel class of PDE4 inhibitors with antioxidant properties as bifunctional agents for the potential treatment of COPD.
Wang Y; Wang H; Yang G; Hao Q; Yang K; Shen H; Wang Y; Wang J
Eur J Med Chem; 2023 Aug; 256():115374. PubMed ID: 37150057
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.
Spina D
Drugs; 2003; 63(23):2575-94. PubMed ID: 14636078
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment.
Zhang R; Li H; Zhang X; Li J; Su H; Lu Q; Dong G; Dou H; Fan C; Gu Z; Mu Q; Tang W; Xu Y; Liu H
Eur J Med Chem; 2021 Feb; 211():113004. PubMed ID: 33218684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
